JP2014068770A - Medicine wrapping sheet, medicine packaging blister pack and medicine package - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a medicine wrapping sheet that can provide a medicine package having excellent transparency, oxygen absorptivity and dampproof properties, and to provide a medicine packaging blister pack, a sealing member and a medicine package that have excellent internal visibility, oxygen absorptivity and dampproof properties.SOLUTION: A medicine wrapping sheet in the invention refers to a medicine wrapping sheet including multiple resin layers, and the sheet has a dampproof layer and an oxygen-absorbing layer. The oxygen-absorbing layer is composed of a resin composition that includes a base resin, an oxygen-absorbing resin and a reaction accelerator. A medicine package in the invention includes the medicine wrapping sheet in the invention.

Description

The present invention relates to a medicine packaging sheet, a medicine packaging blister pack, and a medicine packaging. In particular, the present invention relates to drug packaging sheets used for pharmaceuticals and foods, blister packs for drug packaging, and drug packaging bodies, and more specifically for drug packaging having moisture-proof and oxygen-absorbing properties capable of blocking water vapor and oxygen. The present invention relates to a sheet, a sealing member, a blister pack, and a medicine package.
Here, drug liquids (internal and external liquids), prefilled syringe preparations, extracts, fluid extracts, suspensions, emulsions, jellies, poultices, haptics, tapes, transdermal absorption (type ), Syrup, soak, decoction, gel, cream, ointment, fragrance, elixir, aerosol, spray, spirit, lotion, liniment, limotase, injection, ophthalmic ointment , Eye drops, tinctures, and those containing medicinal ingredients associated therewith. Specific types of chemicals include physiological saline, high-concentration sodium chloride injection, chemicals such as vitamins, minerals, antibiotics, and powdered or lyophilized drugs. In this way, it can be suitably used for pharmaceuticals and foods whose quality, function, efficacy and the like are particularly affected by oxygen.

Conventionally, a plastic container is used as a package for storing medicines and foods.
These are often packaging bodies having water vapor barrier properties and oxygen barrier properties from the viewpoint of protecting the contents. When packaging pharmaceuticals and foods in this plastic container, there are those in which active ingredients such as pharmaceuticals are oxidized and denatured by oxygen remaining inside the plastic container or oxygen entering from the outside. In some cases, the active ingredient is hydrolyzed by water vapor entering from the outside.

Recently, so-called prefilled syringe preparations pre-filled with drugs have been proposed and the amount used has increased. Prefilled syringe formulation reduces the risk of infection by eliminating the trouble of transferring the drug from the ampoule to the syringe. Pre-filled with an accurate dose enables incorrect use and quick administration in the emergency. Its use is widespread because it is simpler and contributes to improving the labor productivity of medical workers.
Since there is a time lag from when the drug is filled into the syringe until administration, the syringe container is required to have a high oxygen barrier property to prevent oxidative degradation of the drug, and a glass container is generally used.

  However, glass is easy to break, difficult to process, and disposal methods. Considering these points, the plastic syringe container is switched. (Patent Documents 1 and 2). However, plastic has the advantage of being inferior in gas barrier properties, although it has the advantage of being lightweight and free from the risk of breakage. Moreover, high airtightness is also required for the gasket and the top cap. For this reason, the plastic syringe container needs to be packaged in a packaging bag having a high oxygen barrier property, and an oxygen scavenger must be enclosed in order to remove oxygen in the package.

  Further, Patent Document 3 discloses a packaging bag using a film having oxygen absorption performance, and Patent Document 4 discloses a secondary container having oxygen absorption performance, which enables deoxidation in the container.

JP 2006-25953 A JP 2011-136773 A JP 2009-154925 A JP 2008-110793 A

Although the prefilled syringe package described in Patent Documents 1 and 2 enables deoxidation in the container, it takes equipment and labor to introduce an oxygen scavenger.
The packaging bag having the oxygen absorption performance of Patent Document 3 uses a stretched film or deposits an inorganic oxide and is not suitable for molding applications. In addition, the secondary container having the oxygen absorption performance of Patent Document 4 has no description and examples relating to moisture resistance, and with this configuration, there is a problem in long-term storage. It is known that the oxygen barrier property of the ethylene-vinyl alcohol copolymer of the oxygen barrier layer decreases due to humidity, and the oxygen barrier property decreases due to the humidity. In the long term, the oxygen concentration inside the container increases. It can be a problem. If a long-term guarantee period such as 3 years is required, it is possible that a malfunction will occur.

  An object of the present invention is to provide a drug packaging sheet that can provide a drug package excellent in transparency, oxygen absorption, and moisture resistance, and a blister for drug packaging excellent in internal visibility, oxygen absorption, and moisture resistance It is to provide a pack, and a drug package.

  Such an object is achieved by the present inventions (1) to (11) below.

(1)
The drug packaging sheet of the present invention includes a moisture-proof layer and an oxygen absorption layer. The moisture-proof layer has a water vapor barrier property. The oxygen absorbing layer is composed of a resin composition containing a base resin, an oxygen absorbing resin, and a reaction accelerator.

  As a result of intensive studies by the inventors of the present application, by using a drug packaging sheet having the above-described configuration, it is possible to provide a drug packaging sheet that can provide a drug package excellent in transparency, oxygen absorption, and moisture resistance. It became clear that we could do it.

(2)
The medicine packaging sheet of the present invention may have an oxygen barrier layer. The oxygen barrier layer has an oxygen barrier property.

  By including the oxygen barrier layer, it is possible to reduce the amount of oxygen absorbed by the oxygen absorbing layer in the medicine packaging sheet or the like per unit time. Therefore, the oxygen absorption layer can maintain oxygen absorptivity for a long time.

(3)
The oxygen barrier layer may have an oxygen absorbing resin B.

  When the oxygen barrier layer has the oxygen-absorbing resin B, the amount of oxygen absorbed by the oxygen-absorbing layer in the medicine packaging sheet or the like per unit time can be further reduced. Therefore, the oxygen absorption layer can maintain oxygen absorptivity for a longer period.

(4)
It is preferable that the said medicine packaging sheet has the said oxygen absorption layer, an oxygen barrier layer, and a moisture-proof layer in this order.

  By having the oxygen absorbing layer, the oxygen barrier layer, and the moisture-proof layer in this order, the amount of oxygen absorbed by the oxygen absorbing layer in the medicine packaging sheet or the like per unit time can be further reduced. Therefore, the oxygen absorption layer can maintain oxygen absorptivity for a longer period of time.

(5)
The oxygen barrier layer preferably has an oxygen permeability of 200 ml / (m ² · 24 h · atm) or less. When an oxygen barrier layer having an oxygen permeability of 200 ml / (m ² · 24 h · atm) or less is used in the drug packaging sheet according to the present invention, the amount of oxygen to be absorbed can be reduced, so that the oxygen absorbing layer Can maintain oxygen absorption for a longer period of time.

(6)
The oxygen-absorbing resin A is preferably contained in an amount of 1% by weight to 80% by weight with respect to the resin composition. The reaction accelerator is preferably contained in a weight ratio of 100 ppm to 10,000 ppm with respect to the resin composition.

  By including the said structure, the oxygen absorptivity of an oxygen absorption layer improves more.

(7)
In the above medicine packaging sheet, the moisture-proof layer is preferably 40 ° C. and 90% RH, and the water vapor permeability at a thickness of 25 μm is 100 g / m ² · day or less.

  By the said structure, the chemical | medical agent package which improved moisture-proof property more can be provided.

(8)
The above-mentioned sheet for packaging medicine preferably has a total light transmittance of 70% or more.

  By using a sheet for drug packaging having a total light transmittance of 70% or more, the transparency of the drug package is improved and the internal visibility of the package is improved. In the above-mentioned medicine packaging sheet, the oxygen absorbing layer is not colored in a unique hue by using the oxygen absorbing resin A without containing an oxygen absorbing agent such as iron powder. For this reason, the oxygen-absorbing resin A can impart transparency to the oxygen-absorbing layer, the drug packaging sheet, and the drug package.

(9)
The blister pack for drug packaging of the present invention is obtained by molding the above-mentioned sheet for drug packaging.

(10)
The medicine packaging body of the present invention includes the above-mentioned medicine packaging sheet.

  The medicine packaging body of the present invention includes the above medicine packaging sheet. For this reason, while the moisture-proof property of a chemical | medical agent package is excellent, while oxygen absorption amount increases, the fall of the internal visibility of a chemical | medical agent package is suppressed.

(11)
The above-mentioned medicine packaging body is a medicine packaging body including a sealing member and a medicine packaging blister pack, and the medicine packaging blister pack preferably includes the above-mentioned medicine packaging blister pack.

(12)
Moreover, the above-mentioned medicine packaging body is a medicine packaging body containing a sealing member and a blister pack for medicine packaging, and the sealing member preferably contains the above-mentioned medicine packaging sheet.

(13)
Moreover, the above-mentioned medicine packaging body is a medicine packaging body including a sealing member and a medicine packaging blister pack, and the sealing member includes the above-mentioned medicine packaging sheet, and the medicine packaging blister pack However, it is more preferable to include a blister pack for drug packaging including the above-mentioned sheet for drug packaging.

  The drug packaging sheet according to the present invention provides a drug packaging sheet that can provide a drug package excellent in transparency, oxygen absorption, and moisture resistance, and is excellent in internal visibility, oxygen absorption, and moisture resistance. A drug package can be provided. As a result, an effect excellent in quality, function and efficacy can be obtained.

It is sectional drawing of the sheet | seat for chemical | medical agent packaging which concerns on one Embodiment of this invention. It is sectional drawing of the sheet | seat for chemical | medical agent packaging which concerns on one Embodiment of this invention. It is sectional drawing of the sheet | seat for chemical | medical agent packaging which concerns on one Embodiment of this invention. It is sectional drawing of the sheet | seat for chemical | medical agent packaging which concerns on one Embodiment of this invention. It is sectional drawing of the sheet | seat for chemical | medical agent packaging which concerns on one Embodiment of this invention. It is sectional drawing of one Embodiment of a medicine package provided with the sheet | seat for medicine packaging. It is an enlarged view of the blister pack part of the package shown in FIG. It is an enlarged view of the sealing member part of the package shown in FIG.

  Hereinafter, the medicine packaging sheet, the medicine packaging blister pack and the medicine packaging body of the present invention will be described in detail.

  The drug packaging sheet of the present invention is a drug packaging sheet including a plurality of resin layers, and the drug packaging sheet has a moisture-proof layer and an oxygen absorption layer, and the oxygen absorption layer is a base resin. And an oxygen-absorbing resin and a reaction accelerator.

  By using the drug packaging sheet having the above-described configuration, the drug packaging sheet can provide a drug packaging sheet that can provide a drug package excellent in transparency, oxygen absorption, and moisture resistance. That is, by setting the oxygen absorbing layer to the above-described configuration, it is possible to provide a drug package having excellent oxygen absorbability, and improve the preservability of the drug. Further, by using the oxygen-absorbing resin A, the transparency of the oxygen-absorbing layer and the drug packaging sheet can be improved, and a drug package excellent in internal visibility can be provided. Moreover, the said packaging sheet can provide the chemical | medical agent package excellent in moisture resistance by having a moisture-proof layer, and can improve the preservability of a chemical | medical agent more. Moreover, the preservability of a chemical | medical agent can be improved more by suppressing the hydrolysis degradation in the content. Furthermore, the oxygen absorbing layer absorbs moisture, thereby preventing the oxygen absorbing resin A and the reaction accelerator from being deactivated, and suppressing the oxygen absorbing properties of the oxygen absorbing layer and the packaging sheet from being lowered. In addition, it is possible to provide a drug package with better oxygen absorbability and further improve the storage stability of the drug.

  Moreover, the sheet | seat for chemical | medical agent packaging of this invention may have an oxygen barrier layer.

  By having the oxygen barrier layer, oxygen can be prevented from newly entering the medicine package from the outside, and the oxygen absorption property of the oxygen absorption layer can be sufficiently exhibited. As a result, it is possible to provide a drug package with better oxygen absorbability and further improve the storage stability of the drug. In addition, the moisture barrier prevents the oxygen barrier property of the oxygen barrier layer from being inhibited by moisture, so that the oxygen barrier layer can sufficiently prevent oxygen from entering from the outside, and the oxygen absorbing property of the oxygen absorbing layer can be reduced. Decline can be prevented. Thereby, the chemical | medical agent package which oxygen absorption was more excellent can be provided, and the preservability of a chemical | medical agent can be improved more.

  The blister pack for drug packaging of the present invention can be obtained by molding the sheet for drug packaging.

  The blister pack for drug packaging according to the present invention includes the sheet for drug packaging, thereby preventing moisture from entering the drug package through the blister pack for drug packaging and quickly increasing the oxygen concentration in the drug package. Can be reduced. Thereby, when it is set as a chemical | medical agent package, the preservability of a chemical | medical agent can be improved.

  The medicine packaging body of the present invention is a medicine packaging body including a sealing member and a medicine packaging blister pack, and the medicine packaging blister pack preferably includes the medicine packaging sheet.

  The drug packaging body of the present invention is configured such that the drug packaging blister pack includes the drug packaging sheet, thereby preventing moisture from entering the drug package through the drug packaging blister pack. The oxygen concentration of can be quickly reduced. Thereby, the preservability of a medicine can be improved.

  The medicine packaging body of the present invention is a medicine packaging body including a sealing member and a medicine packaging blister pack, and the sealing member preferably includes the medicine packaging sheet.

  In the drug package of the present invention, the sealing member includes the drug packaging sheet, thereby preventing moisture from entering the drug package through the sealing member and reducing the oxygen concentration in the drug package. It can be quickly reduced. Thereby, the preservability of a medicine can be improved.

  The drug packaging body of the present invention is a drug packaging body including a sealing member and a blister pack for drug packaging, wherein the sealing member includes the sheet for drug packaging, and the blister pack for drug packaging includes: More preferably, it includes the drug packaging sheet.

  In the medicine packaging body of the present invention, the sealing member includes the medicine packaging sheet, and the medicine packaging blister pack includes the medicine packaging sheet. It is possible to prevent moisture from entering the medicine package through both blister packs, and to reduce the oxygen concentration in the medicine package more rapidly. Thereby, the preservability of a medicine can be improved.

  Hereinafter, the medicine packaging sheet of the present invention will be described in detail based on the embodiments shown in the drawings.

  Although the drug packaging sheet according to the present invention is not particularly limited, for example, as shown in FIG. 1, a moisture-proof layer 110, a first adhesive layer 120, an oxygen barrier layer 130, a second adhesive layer 140, an oxygen absorbing layer 150, Examples thereof include the drug packaging sheet 100 in which the seal layer 160 is formed by being laminated in this order. Although this medicine packaging sheet 100 is not particularly limited, it can be used for the medicine packaging blister pack 300 or the sealing member 400 in the medicine packaging blister pack 300 of the medicine packaging 200 as shown in FIG. Here, the medicine packaging blister pack 300 and the sealing member 400 can also be used. It can be said that the blister pack for drug packaging is used as the bottom material of the drug package, and the sealing member is used as a lid for the drug package. Hereinafter, each structure of the medicine packaging sheet 100 will be described in detail.

(1) Moisture-proof layer The chemical | medical agent packaging sheet 100 contains the moisture-proof layer 110 as shown in FIG.
The material of the moisture-proof layer 110 is not particularly limited, but it is often used as an outer layer of a medicine package, and therefore has a strength that can be used as a bottom material or a lid of the medicine package. Is preferred. Further, the material of the moisture-proof layer is 40 ° C. and 90% RH, and the water vapor permeability at a thickness of 25 μm is preferably 100 g / m ² · day or less, more preferably 20 g / m ² · day or less. By being within the preferable range, when a medicine package is obtained, it is possible to suitably prevent moisture from entering and improve the preservability of the medicine. Although it does not specifically limit as a material of such a moisture-proof layer, It is preferable that a thermoplastic resin is included. For example, polyethylene, polypropylene, polyvinyl chloride, polyvinylidene chloride, polychlorotrifluoroethylene, polystyrene, polyethylene, polyamide, polyethylene terephthalate, cyclic olefin polymer, cyclic olefin copolymer, petroleum resin, polytetrafluoroethylene, polyvinyl fluoride, polyvinyl fluoride. And fluorinated resin copolymers such as vinylidene fluoride and ethylene / tetrafluoroethylene copolymer. The moisture-proof layer material may include a plurality of these materials.

  The moisture-proof layer 110 may be one or more layers, and may have a two-layer structure including the auxiliary moisture-proof layer 110A as shown in FIG. In order to have higher moisture resistance, the above-described resins may be laminated. Examples of the laminating method include a dry laminating method, an extrusion laminating method, a hot melt laminating method, a wet laminating method, and a thermal (thermal) laminating method. Also, a method of coating a resin having a gas barrier property, a method of depositing a thin film by depositing an inorganic oxide or metal such as aluminum metal, silicon oxide (silica) or aluminum oxide (alumina), an organic barrier layer or an organic / inorganic composite Multilayering may be performed by a coating method such as a method of coating a barrier layer.

  The thickness of the moisture-proof layer 110 is not particularly limited, but is preferably 5 μm or more and 1000 μm or less, and more preferably 10 μm or more and 600 μm or less. By being more than the said lower limit, sufficient moisture-proof property can be ensured, and sufficient moldability can be ensured by being the said upper limit or less.

(2) First Adhesive Layer The drug packaging sheet 100 may include a first adhesive layer 120 as shown in FIG. The material of the first adhesive layer 120 is not particularly limited, but a known adhesive resin can be used. Especially, it is preferable to select with resin used as an adjacent layer (for example, moisture-proof layer), for example, adhesive polyolefin resin etc. are used. Specifically, as the material of the first adhesive layer 120, for example, ethylene-methacrylate-glycidyl acrylate terpolymer, or various polyolefins, monobasic unsaturated fatty acid, dibasic unsaturated fatty acid, or these An anhydride grafted (maleic acid grafted ethylene-vinyl acetate copolymer, maleic acid grafted ethylene-α-olefin copolymer, etc.) and the like are used. Examples of monobasic unsaturated fatty acids include acrylic acid and methacrylic acid. Examples of the dibasic unsaturated fatty acid include maleic acid, fumaric acid, itaconic acid and the like.

  The first adhesive layer 120 may contain an antioxidant. When the first adhesive layer 120 contains an antioxidant, examples of the antioxidant include known antioxidants, such as hindered phenol-based antioxidants, phosphorus-based antioxidants, thioether-based antioxidants, Used alone or in combination of two or more.

  Although the thickness of the 1st contact bonding layer 120 is not specifically limited, 3 micrometers or more and 100 micrometers or less are preferable, and 5 micrometers or more and 50 micrometers or less are preferable. When it is at least the lower limit value, sufficient adhesion can be ensured, and when it is at most the upper limit value, problems such as bleeding of the first adhesive layer can be prevented.

(3) Oxygen Barrier Layer The drug packaging sheet 100 may include an oxygen barrier layer 130 as shown in FIG.
When the oxygen barrier layer 130 is used as a medicine package, it can restrict the permeation of oxygen entering from the outside, and thereby the oxygen concentration inside the medicine package can be rapidly reduced. This can limit the permeation of oxygen entering from the outside of the drug package 200 as shown in FIG. 6, for example, and thereby the oxygen concentration inside the drug package 200 can be quickly reduced. . Thereby, the preservability of a chemical | medical agent can be improved more. As a material of the oxygen barrier layer 130, a known material having an oxygen barrier property, for example, a polyvinyl alcohol resin, an ethylene-vinyl alcohol copolymer resin (hereinafter referred to as “EVOH resin”), a polyvinylidene chloride resin, or A polyamide resin having an aromatic ring in the diamine component, polyacrylonitrile, or the like is used. As the oxygen barrier layer, a material obtained by blending the oxygen-absorbing resin B with the above-described known material having oxygen barrier properties to obtain a further oxygen high barrier material may be used. Such a material is not particularly limited. For example, an EVOH resin containing the oxygen absorbing resin B, a polyamide resin containing the oxygen absorbing resin B, a polyester resin containing the oxygen absorbing resin B, and the like can be used. .
The oxygen-absorbing resin B is not particularly limited, and for example, an unsaturated polyolefin-based oxygen-absorbing resin is used. More specifically, for example, ethylenically unsaturated hydrocarbon polymer, main chain ethylenically unsaturated hydrocarbon polymer, polyether unit polymer, copolymer of ethylene and distorted cyclic alkylene, polyamide resin, acid-modified polybutadiene, hydroxyaldehyde Polymers, polyisoprene, styrene / butadiene copolymers, styrene / isoprene copolymers, and the like can be used alone or in combination.
The oxygen barrier layer may be formed by laminating these materials in multiple layers, such as two layers including the auxiliary oxygen barrier layer 131A, as in the drug packaging sheet 100B shown in FIG. The EVOH resin is obtained, for example, by saponifying an ethylene vinyl acetate copolymer. The oxygen barrier layer 130 preferably has an oxygen permeability of 200 ml / (m ² · 24 h · atm) or less, more preferably 10 ml / (m ² · 24 h · atm) or less, and an oxygen permeability of 2 ml. / (M ² · 24h · atm) or less is more preferable. By being below the upper limit value, a sufficient decrease in oxygen concentration can be realized when a medicine package is obtained. Such oxygen permeability is not particularly limited, but can be measured by a method of measuring in accordance with JIS K 7126B.

  The thickness of the oxygen barrier layer 130 is not particularly limited, but is preferably 3 μm or more and 800 μm or less, and more preferably 5 μm or more and 400 μm or less. By being more than the said lower limit, sufficient oxygen barrier property and the fall of oxygen concentration can be implement | achieved, and the moldability of a packaging sheet can be improved by being below the said upper limit.

(4) Second Adhesive Layer The drug packaging sheet 100 may include a second adhesive layer 140 as shown in FIG. The material of the second adhesive layer 140 is not particularly limited, but a known adhesive resin can be used. For example, an adhesive polyolefin resin is used. Specifically, as the material of the second adhesive layer 140, for example, an ethylene-methacrylate-glycidyl acrylate terpolymer, or various polyolefins to a monobasic unsaturated fatty acid, a dibasic unsaturated fatty acid, or these An anhydride grafted (maleic acid grafted ethylene-vinyl acetate copolymer, maleic acid grafted ethylene-α-olefin copolymer, etc.) and the like are used. Examples of monobasic unsaturated fatty acids include acrylic acid and methacrylic acid. Examples of the dibasic unsaturated fatty acid include maleic acid, fumaric acid, itaconic acid and the like.

  The second adhesive layer 140 may contain an antioxidant. When the second adhesive layer 140 contains an antioxidant, examples of the antioxidant include known antioxidants, such as hindered phenol antioxidants, phosphorus antioxidants, thioether antioxidants, Used alone or in combination of two or more.

  Although the thickness of the 2nd contact bonding layer 140 is not specifically limited, 3 micrometers or more and 100 micrometers or less are preferable, and 5 micrometers or more and 50 micrometers or less are preferable. When it is at least the lower limit value, sufficient adhesion can be ensured, and when it is at most the upper limit value, problems such as bleeding of the second adhesive layer can be prevented.

(5) Oxygen Absorbing Layer The drug packaging sheet 100 includes an oxygen absorbing layer 150 as shown in FIG. The oxygen absorbing layer 150 is composed of a resin composition including a base resin, an oxygen absorbing resin A that is an oxygen absorbent, and a reaction accelerator. The oxygen-absorbing resin A is not particularly limited. For example, an unsaturated polyolefin-based oxygen absorbing resin is used. More specifically, for example, ethylenically unsaturated hydrocarbon polymer, main chain ethylenically unsaturated hydrocarbon polymer, polyether unit polymer, copolymer of ethylene and distorted cyclic alkylene, polyamide resin, acid-modified polybutadiene, hydroxyaldehyde Polymers, polyisoprene, styrene / butadiene copolymers, styrene / isoprene copolymers, and the like can be used alone or in combination.

  The content of the oxygen-absorbing resin A is not particularly limited, but is preferably 1 to 80% by weight, preferably 5 to 60% by weight, based on the resin composition. More preferably. By being above the lower limit value, sufficient oxygen absorbability can be realized, and by being below the upper limit value, an effect of internal visibility can be obtained.

  On the other hand, the reaction accelerator is not particularly limited, and examples thereof include a radical generator, a photocatalyst and a transition metal compound, and two or more of these may be used in combination. Among these, a transition metal compound is preferable, and the reactivity between oxygen and the polymer having an unsaturated bond can be further increased by including the transition metal compound. By increasing the reactivity in this manner, oxygen can be efficiently removed in a short time, and there is an effect of further improving the storage stability of the contents when the package is made. The transition metal compound is not particularly limited, and for example, zinc stearate, cobalt stearate, cobalt naphthenate, zinc naphthenate, acetylacetonate zinc, acetylacetonate cobalt or acetylacetonate copper is preferable.

The content of the reaction accelerator is not particularly limited, but is preferably 100 ppm or more and 10,000 ppm or less, more preferably 300 ppm or more and 5000 ppm or less, and more preferably 500 ppm or more and 5000 ppm or less with respect to the whole resin composition. Is more preferably 700 ppm or more and 5000 ppm or less, and further preferably 1000 ppm or more and 5000 ppm or less.
Sufficient oxygen absorptivity can be realized by being above the lower limit, and coloring by the reaction accelerator can be suppressed by being below the upper limit. Thus, adjusting the content of the reaction accelerator contained in the oxygen absorbing layer can be realized by setting the content of the reaction accelerator in the resin composition within the above range.

  Although it does not specifically limit as said base resin, The thing which does not affect the transparency of an oxygen absorption layer is preferable. For example, a polyamide-type resin, a polyethylene-type resin, a polypropylene-type resin, and a polyester-type resin are mentioned, You may use these 2 or more types together. By including such a resin, the strength of the oxygen absorption layer 150 can be increased. Thereby, the intensity | strength of the sheet | seat for medicine packaging and a medicine packaging body can be raised. As a result, it is possible to prevent problems such as unintentional breakage that occur at the time of manufacture of the drug package or transport of the drug package.

  The content of the base resin is not particularly limited, but is preferably 20 to 99% by weight, and preferably 40 to 95% by weight with respect to the resin composition. More preferable. Dispersibility of the oxygen-absorbing resin A and the reaction accelerator is improved by being at least the lower limit, and sufficient oxygen absorbability can be obtained by being at most the upper limit.

  The oxygen absorption layer 150 may contain an antioxidant. When the oxygen absorbing layer 150 contains an antioxidant, examples of the antioxidant include known antioxidants such as hindered phenol antioxidants, phosphorus antioxidants, thioether antioxidants, and the like. Or a mixture of two or more. The content of the antioxidant in the oxygen absorbing layer 150 is preferably 170 ppm or less, more preferably 5 ppm or more and 120 ppm or less, and more preferably 35 ppm or more and 60 ppm or less with respect to the resin composition. Further preferred. By being in the preferred range, sufficient oxygen absorbability can be realized.

  Moreover, the oxygen absorption layer 150 can contain an additive, a compatibilizing agent, etc. in the range which does not impair a physical property. Inclusion of such an additive has the effect of promoting the oxygen absorption reaction.

  The thickness of the oxygen absorbing layer 150 is not particularly limited, but is preferably 3 μm or more and 700 μm or less, and more preferably 5 μm or more and 300 μm or less. By being above the lower limit value, sufficient oxygen absorption, when the drug packaging body is made, a reduction in oxygen concentration inside the medicine packaging body can be realized, and by being below the upper limit value, for packaging The formability of the sheet can be improved.

(6) Seal Layer The drug packaging sheet 100 may include a seal layer 160 as shown in FIG.
The seal layer 160 is not particularly limited, and has, for example, a function of sealing a lid material and a bottom material in a medicine package. For example, in FIG. 6, the sealing member 400 is sealed to the medicine packaging blister pack 300 (heat seal, It has a sealing function for ultrasonic sealing, high-frequency sealing, impulse sealing, etc.) and does not adversely affect the contents accommodated in the medicine package 200. The material of the seal layer 160 includes low density polyethylene (LDPE) resin, linear low density polyethylene (LLDPE) resin, medium density polyethylene (MDPE) resin, high density polyethylene (HDPE) resin, polypropylene (PP) resin, ethylene -Vinyl acetate copolymer (EVA) resin, ethylene-methyl methacrylate copolymer (EMMA) resin, ethylene-ethyl acrylate copolymer (EEA) resin, ethylene-methyl acrylate copolymer (EMA) resin, ethylene-ethyl Acrylate-maleic anhydride copolymer (E-EA-MAH) resin, ethylene-acrylate copolymer (EAA) resin, ethylene-methacrylic acid copolymer (EMAA) resin, ionomer (ION) resin, etc. Or two or more types are used in combination.

  The seal layer 160 may contain an antioxidant. When the seal layer 160 contains an antioxidant, examples of the antioxidant include known antioxidants such as hindered phenol antioxidants, phosphorus antioxidants, thioether antioxidants, and the like. Or two or more types are used in combination.

  The seal layer 160 may include a chemical deodorant. As the chemical deodorant, a known substance that chemically adsorbs the odor-causing substance is used, and is appropriately selected according to the target odor-causing substance. Specifically, when the target odor-causing substance is an aldehyde, as the deodorant, for example, amine compound-supporting silicon dioxide, a composite of an amine organic compound and a silicate inorganic compound, an amino group between layers A layered phosphate or the like that holds is used. When the target odor-causing substance is an acid, examples of the deodorizer include hydroxyl-supported zirconium, aluminosilicate, and hydroxyl-supported zinc oxide. The chemical deodorant is added to a known binder resin by, for example, a usual master batch blending method at the time of melt extrusion. Since this laminated film 100 has a chemical deodorant, the appearance (rough skin, transparency) becomes better than a laminated film having a physical deodorant.

  The thickness of the seal layer 160 is not particularly limited, but is preferably 3 μm or more and 200 μm or less, and more preferably 5 μm or more and 50 μm or less. When it is at least the lower limit, sufficient sealing properties can be secured, and when it is at most the upper limit, problems such as seepage of the seal layer can be prevented.

  Further, the drug packaging sheet 100 is different from the seal layer 160 in that the deodorizing layer 170 containing the above deodorant is separated from the sealing layer 160 like the drug packaging sheet 100C and the drug packaging sheet 100D shown in FIGS. Further layers may be included. The deodorizing layer 170 can be manufactured by using a known binder resin at the time of melt extrusion of the chemical deodorant.

  Although the thickness of the deodorizing layer 170 is not specifically limited, 3 micrometers or more and 200 micrometers or less are preferable, and 5 micrometers or more and 50 micrometers or less are preferable. By being more than the said lower limit, sufficient deodorizing effect can be acquired, and internal visibility is not inhibited by being below the said upper limit.

<Method for producing sheet for drug packaging>
The method for producing the drug packaging sheet is not particularly limited, but a co-extrusion T-die method such as a feed block method or a multi-manifold method in which a raw material resin is melt-extruded by several extruders, air cooling, and the like. Or a water-cooled coextrusion inflation method. Among them, a method of forming a film by the coextrusion T-die method is particularly preferable because it is excellent in controlling the thickness of each layer. As a subsequent process, a single layer sheet or film forming each layer is bonded using an appropriate adhesive, a dry laminating method, an extrusion laminating method, a hot melt laminating method, a wet laminating method, a thermal (thermal) laminating method, and the like. Used in combination of methods. Moreover, you may laminate | stack by the method by coating.

  The thickness of the drug packaging sheet thus obtained is not particularly limited, but is preferably 30 μm or more and 2000 μm or less, and more preferably 50 μm or more and 800 μm or less. By being more than the said lower limit, the effect of moisture-proof and oxygen absorptivity can be acquired, and the effect of favorable visibility can be acquired by being below the said upper limit.

  Further, the drug packaging sheet is not particularly limited, but the total light transmittance is preferably 70% or more, and more preferably 80% or more. By being more than the said lower limit, transparency when it is set as a medicine packaging body can fully be secured, and the visibility inside a medicine packaging body can be improved. Here, the total light transmittance can be measured using a haze meter.

  In addition, the sheet for drug packaging is a crystal nucleating agent, petroleum resin, elastomer, antistatic agent, ultraviolet absorber, lubricant, antioxidant, light stabilizer, antiblocking agent, and surface active agent as long as the basic performance is not impaired. An additive such as an agent, a dye, a pigment, a flame retardant, and a plasticizer may be added to one or more layers included in the drug packaging sheet. By including such a layer, the sheet for drug packaging and the drug package can include an antistatic function, an ultraviolet ray preventive function, and the like, and the preservability of the contents of the drug package can be further improved. .

<Blister pack for drug packaging and drug package>
Hereinafter, the blister pack for drug packaging and the drug package of the present invention will be described in detail based on the embodiments shown in the drawings.

As shown in FIG. 6, the drug package 200 is not particularly limited, but can be composed of a drug packaging blister pack 300 and a sealing member 400.
In the medicine packaging blister pack 300, the medicine packaging blister is formed by forming the pocket 210 with the moisture-proof layer 110 on the outside and the seal layer 160 on the inside as shown in FIG. A pack can be used. As shown in FIG. 8, the sealing member 400 can also be used as the sealing member with the moisture-proof layer 110 on the outside and the sealing layer 160 on the inside.

  When the medicine packaging sheet of the present invention is formed into a medicine packaging blister pack and used as a medicine packaging blister pack in a medicine packaging body, the material of the sealing member is not particularly limited. Metal foil such as aluminum foil coated with an agent, biaxially stretched polypropylene film (OPP film), biaxially stretched polyethylene terephthalate film (VM-PET film) deposited with metal oxide, or film laminated with polyethylene resin, etc. May be used. Moreover, you may use the sheet | seat for chemical | medical agent packaging of this invention. The pocket of the medicine packaging blister pack contains contents such as medicine. After the contents are accommodated in the pocket, the sealing member is sealed in the blister pack for drug packaging, and the pocket is sealed.

  When a drug packaging sheet is used as a sealing member in the drug package, the material for the blister pack for drug packaging is not particularly limited. For example, Sumilite CEL-R111B or CEL-R161A (manufactured by Sumitomo Bakelite Co., Ltd.) Can be mentioned. In addition, containers made of metals such as aluminum, containers manufactured by a method of depositing inorganic oxides such as silicon oxide (silica) and aluminum oxide (alumina) after forming, and coating with metal and inorganic thin films are used. May be. Moreover, you may use the sheet | seat for chemical | medical agent packaging of this invention. The blister pack pocket contains contents such as drugs. After the contents are stored in the pocket, the sealing member is sealed in the blister pack for drug packaging, and the pocket of the blister pack for drug packaging is sealed.

<Effect in this embodiment>
This medicine packaging sheet is excellent in blocking water vapor from the outside, and has an oxygen absorbing layer, so it is excellent in blocking oxygen from the outside and can remove internal oxygen, thus protecting the contents. ing.

  Next, Examples 1 to 7 and Comparative Examples 1 and 2 relating to a medicine package including the medicine packaging sheet of the present invention will be described. In addition, this invention is not limited at all by these Examples.

Example 1
<Production of sheet>
As a resin constituting the moisture-proof layer, a polypropylene resin (manufactured by Prime Polymer Co., Ltd., product number: E122V) and an elastomeric propylene copolymer (manufactured by Mitsui Chemicals, product number: XM7080) were prepared. An adhesive polyolefin resin (manufactured by Nippon Polyolefin Co., Ltd., product number: ER313E-1) was prepared as a resin constituting the first adhesive layer. As a resin constituting the oxygen barrier layer, an EVOH resin containing oxygen absorbing resin (manufactured by Kuraray Co., Ltd., product number: AP931) was prepared. An adhesive polyolefin resin (manufactured by Mitsui Chemicals, product number: LF308) was prepared as a resin constituting the second adhesive layer. Resin in which metallocene LLDPE resin (manufactured by Ube Maruzen Polyethylene Co., Ltd., product number: 125FN) is mixed as a base resin in a proportion of 80% by weight and unsaturated polyolefin oxygen-absorbing resin in a proportion of 20% by weight as a resin constituting the oxygen absorbing layer A composition was prepared. As a resin constituting the seal layer, a metallocene PP resin (manufactured by Nippon Polypro Co., Ltd., product number: WFX4) was prepared.

  Furthermore, as the resin constituting the oxygen absorbing layer, the resin composition in which the base resin and the unsaturated polyolefin oxygen absorbing resin are mixed is reacted so that the content is 1000 ppm by weight with respect to the resin composition. An accelerator, cobalt stearate, was added.

  A metallocene PP resin constituting a sealing layer, a resin composition constituting an oxygen absorbing layer, an adhesive polyolefin resin constituting a second adhesive layer, an EVOH resin constituting an oxygen barrier layer, and a first adhesive layer The adhesive polyolefin-based resin constituting and the polypropylene resin constituting the moisture-proof layer were coextruded in this order to produce a drug packaging sheet (see FIG. 1). In the obtained drug packaging sheet, the thickness of the sealing layer is 35 μm, the thickness of the oxygen absorbing layer is 90 μm, the thickness of the second adhesive layer is 25 μm, the thickness of the oxygen barrier layer is 75 μm, The thickness was 25 μm, the thickness of the moisture-proof layer was 250 μm, and the total thickness of the sheet was 500 μm.

<Transparency of sheet>
The total light transmittance of the obtained drug packaging sheet was measured based on JIS K7361.

  Regarding the total light transmittance of the drug packaging sheet, it was evaluated as ◯ when it was 80% or more, Δ when it was less than 80% and 70% or more, and × when it was less than 70%.

  The obtained drug packaging sheet had a total light transmittance of 84%, and was marked as ◯.

<Water vapor permeability of sheet>
The water vapor permeability of the resin constituting the moisture-proof layer and the obtained drug packaging sheet was measured based on JIS K7129. As for the water vapor permeability of the resin constituting the moisture-proof layer, only the resin constituting the moisture-proof layer was extruded as a single layer to produce a sheet, the water vapor permeability was measured, and the water vapor permeability at 25 μm was determined.

Regarding the water vapor permeability of the drug packaging sheet, it was evaluated as ○ when it was 3.0 g / m ² · day or less, and × when it exceeded 3.0 g / m ² · day.

The water vapor permeability at 25 μm of the resin constituting the moisture-proof layer was 9.3 g / m ² · day, and the water vapor permeability of the drug packaging sheet was 0.54 g / m ² · day · atm. The water vapor transmission rate of the drug packaging sheet was evaluated as ◯.

<Production of blister pack for drug packaging and drug package>
Create a pocket (long side 160mm x short side 105mm x depth 30mm) using a vacuum forming machine, and insert a PSt3 type sensor chip for oxygen concentration measurement (PreSens, detection limit: 0.01%) and cover Sealed with an aluminum laminate film (PET layer 12 μm / PE layer 15 μm / AL layer 9 μm / PE layer 34 μm) to prepare a medicine package.

<Measurement of oxygen absorption>
As shown in FIG. 6, an oxygen concentration measurement at 25 ° C. was performed using a non-contact oxygen concentration meter 500 (manufactured by PreSens, product number: Fibox 3 LCD) and a sensor chip 510.

  When the oxygen concentration 10 days after the formation of the drug package is less than 5% with respect to the initial oxygen concentration, ◎ when it is 5% or more and less than 20%, △ when it is 20% or more and less than 50% When it was 50% or more, it was set as x.

  The oxygen concentration after 10 days of the obtained drug package was 0.99%, which was 4.7 because of the initial oxygen concentration.

(Example 2)
Materials other than those described below were prepared in the same manner as in Example 1 to prepare a drug packaging sheet material. As the resin constituting the oxygen absorbing layer, a mixture of 40% by weight of the base resin and 60% by weight of the unsaturated polyolefin oxygen absorbing resin was prepared. As a resin constituting the deodorant layer, LLDPE resin (manufactured by Prime Polymer Co., Ltd., product number: 0248Z) and 2% by weight of a chemical deodorant, amine-based compound-supported silicon dioxide (Toa Gosei Co., Ltd.) Manufactured, product number: Kesmon NS-241). As a resin constituting the seal layer, an LLDPE resin (manufactured by Prime Polymer Co., Ltd., product number: 0248Z) was prepared.

  Furthermore, the resin composition in which the base resin and the unsaturated polyolefin-based oxygen-absorbing resin are mixed as the resin constituting the oxygen-absorbing layer is reacted so that the content is 2000 ppm by weight with respect to the resin composition. An accelerator, cobalt stearate, was added.

  LLDPE resin constituting the sealing layer, deodorant and base resin constituting the deodorizing layer, resin composition constituting the oxygen absorbing layer, adhesive polyolefin resin constituting the second adhesive layer, and oxygen barrier An EVOH resin containing an oxygen-absorbing resin constituting the layer, an adhesive polyolefin resin constituting the first adhesive layer, and a polypropylene resin constituting the moisture-proof layer were coextruded in this order to produce a drug packaging sheet. (See FIG. 4). In the obtained drug packaging sheet, the thickness of the sealing layer is 16 μm, the thickness of the deodorizing layer is 16 μm, the thickness of the oxygen absorbing layer is 60 μm, the thickness of the second adhesive layer is 20 μm, and the thickness of the oxygen barrier layer The thickness was 80 μm, the thickness of the first adhesive layer was 20 μm, the thickness of the moisture-proof layer was 188 μm, and the total thickness of the sheet was 400 μm.

  As a result of measuring the total light transmittance of this sheet for packaging medicine, it was 82%, and it was marked as ◯.

The water vapor permeability of the drug packaging sheet was 0.6 g / m ² · day. The water vapor transmission rate of the drug packaging sheet was evaluated as ◯.

<Production of lid material>
An LLDPE resin (manufactured by Prime Polymer Co., Ltd., product number: ULT ZEXX 2022L) was formed into a film by a T-die extrusion method to obtain an LLDPE film having a thickness of 30 μm. This LLDPE film, a biaxially stretched polypropylene film (OPP film) with a thickness of 30 μm, and a 12 μm thick biaxially stretched polyethylene terephthalate film (VM-PET film) subjected to aluminum vapor deposition are bonded together by a dry laminating method, A sheet A for a sealing member, which is a multilayer sheet (hereinafter also simply referred to as “lid material A”), was produced.

<Production of blister pack for drug packaging and drug package>
A pocket (long side 180 mm, short side 70 mm, height 20 mm) was created by a vacuum forming machine, a PSt3 type sensor chip for measuring oxygen concentration was introduced, and sealed with the lid material A to prepare a medicine package.

  The oxygen concentration after 10 days of this package was 0.00%, which was 0.0% of the initial oxygen concentration.

(Example 3)
The drug packaging sheet produced in Example 2 was laminated with a 23 μm-thick polychlorotrifluoroethylene to obtain a drug packaging sheet (see FIG. 2).

  As a result of measuring the total light transmittance of this sheet for packaging medicine, it was 80%, and it was marked as ◯.

The water vapor permeability of the drug packaging sheet was 0.2 g / m ² · day. The water vapor transmission rate of the drug packaging sheet was evaluated as ◯.

<Production of blister pack for drug packaging and drug package>
Using the obtained drug packaging sheet, a pocket (long side 150 mm, short side 80 mm, height 25 mm) was created by a vacuum forming machine, and a PSt3 type sensor chip for measuring oxygen concentration was introduced. Sealed to produce a drug package.

The oxygen concentration after 10 days of this package was 1.83%, and it was ◯ because it was 8.8% of the initial oxygen concentration.

Example 4
Materials other than those described below were prepared in the same manner as in Example 1 to prepare a drug packaging sheet material. Copolymerized polyester resin (manufactured by Eastman Chemical Japan Co., Ltd., product number: GN071) was prepared as a resin constituting the moisture-proof layer, and EVOH resin (manufactured by Kuraray Co., Ltd., product number: J171B) was prepared as the resin constituting the oxygen barrier layer. . As the resin constituting the oxygen absorbing layer, a resin composition was prepared in which 90% by weight of the base resin and 10% by weight of the unsaturated polyolefin oxygen absorbing resin were mixed.

  Further, the resin composition in which the base resin and the unsaturated polyolefin-based oxygen-absorbing resin are mixed as the resin constituting the oxygen-absorbing layer is reacted so that the content is 4000 ppm by weight with respect to the resin composition. An accelerator, cobalt stearate, was added.

  A metallocene PP resin constituting a sealing layer, a resin composition constituting an oxygen absorbing layer, an adhesive polyolefin resin constituting a second adhesive layer, an EVOH resin constituting an oxygen barrier layer, and a first adhesive layer The adhesive polyolefin resin constituting and the copolyester resin constituting the moisture-proof layer were coextruded in this order to produce a drug packaging sheet (see FIG. 4). In the obtained drug packaging sheet, the thickness of the seal layer is 40 μm, the thickness of the oxygen absorption layer is 144 μm, the thickness of the second adhesive layer is 48 μm, the thickness of the oxygen barrier layer is 120 μm, The thickness was 48 μm, the thickness of the moisture-proof layer was 400 μm, and the total thickness of the sheet was 800 μm.

  The total light transmittance of this drug packaging sheet was measured and found to be 78%, which was indicated by Δ.

The water vapor permeability of the drug packaging sheet was 0.6 g / m ² · day. The water vapor transmission rate of the drug packaging sheet was evaluated as ◯.

<Production of blister pack for drug packaging and drug package>
Using the obtained drug packaging sheet, a pocket (long side 150 mm, short side 80 mm, height 25 mm) was created by a vacuum forming machine, and a PSt3 type sensor chip for measuring oxygen concentration was introduced. Sealed to produce a drug package.

  The oxygen concentration after 10 days of this package was 3.72%, and the initial oxygen concentration was 27.8%.

(Example 5)
<Production of sheet>
A polypropylene resin (manufactured by Prime Polymer Co., Ltd., product number: E122V) was prepared as a resin constituting the moisture-proof layer. An adhesive polyolefin resin (manufactured by Nippon Polyolefin Co., Ltd., product number: ER313E-1) was prepared as a resin constituting the first adhesive layer. As a resin constituting the oxygen barrier layer, an EVOH resin (manufactured by Kuraray Co., Ltd., product number: J171B) was prepared. In addition, polyamide resin (Mitsubishi Gas Chemical Co., Ltd., product number: S6007) is used as a resin constituting the auxiliary oxygen barrier layer, and adhesive polyolefin resin (Mitsui Chemicals Co., Ltd., product number: as the resin constituting the second adhesive layer). LF308) was prepared. As the resin constituting the oxygen absorbing layer, a mixture of 50% by weight of the base resin and 15% by weight of the unsaturated polyolefin-based oxygen absorbing resin was prepared. As a resin constituting the deodorizing layer, LLDPE resin (manufactured by Prime Polymer Co., Ltd., product number: 0248Z) and 5% by weight of amine-based compound-supporting silicon dioxide (Toagosei Co., Ltd.) as a chemical deodorant Manufactured, product number: Kesmon NS-241). As a resin constituting the seal layer, an LLDPE resin (manufactured by Prime Polymer Co., Ltd., product number: 0248Z) was prepared.

  Further, the resin composition obtained by mixing the base resin of the oxygen absorbing layer and the unsaturated polyolefin oxygen absorbing resin is stearin as a reaction accelerator so that the content is 1500 ppm by weight with respect to the resin composition. Cobalt acid was added.

  LLDPE resin constituting the sealing layer, deodorant and base resin constituting the deodorizing layer, resin composition constituting the oxygen absorbing layer, adhesive polyolefin resin constituting the second adhesive layer, and auxiliary oxygen Polyamide resin that constitutes the barrier layer, EVOH resin that constitutes the oxygen barrier layer, adhesive polyolefin resin that constitutes the first adhesive layer, and polypropylene resin that constitutes the moisture-proof layer are coextruded in this order, and drug packaging A sheet was prepared (see FIG. 3). In the obtained drug packaging sheet, the thickness of the sealing layer is 20 μm, the thickness of the deodorizing layer is 20 μm, the thickness of the oxygen absorbing layer is 100 μm, the thickness of the second adhesive layer is 25 μm, the auxiliary oxygen barrier layer The thickness was 25 μm, the thickness of the oxygen barrier layer was 50 μm, the thickness of the first adhesive layer was 25 μm, the thickness of the moisture-proof layer was 235 μm, and the total thickness of the sheet was 500 μm.

  The total light transmittance of this drug packaging sheet was 83%, which was good.

The water vapor permeability at 25 μm of the resin constituting the moisture-proof layer was 9.1 g / m ² · day, and the water vapor permeability of the drug packaging sheet was 0.5 g / m ² · day · atm. The water vapor transmission rate of the drug packaging sheet was evaluated as ◯.

<Production of blister pack for drug packaging and drug package>
Using the obtained drug packaging sheet, a pocket (long side 150 mm, short side 80 mm, height 25 mm) was created by a vacuum forming machine, and a PSt3 type sensor chip for measuring oxygen concentration was introduced. Sealed to produce a drug package.

  The oxygen concentration after 10 days of this drug package was 0.00%, which was 0.0% of the initial oxygen concentration, and was marked as ◎.

(Comparative Example 1)
A drug packaging sheet was obtained in the same manner as in Example 1 except that no oxygen-absorbing resin was used.

  The oxygen concentration after 10 days of this drug package was 20.7%, which was 99.0% of the initial oxygen concentration, and was evaluated as x.

(Comparative Example 2)
A drug packaging sheet was obtained in the same manner as in Example 1 except that no reaction accelerator was added.

  The oxygen concentration after 10 days was 20.3%, which was 97.1% of the initial oxygen concentration, and was marked as x.

  As apparent from Table 1, the drug packaging sheet according to the present invention is excellent in moisture resistance, oxygen absorption, and moldability.

  Since the drug packaging sheet, the drug packaging blister pack, the sealing member, and the drug package according to the present invention are excellent in moisture resistance and oxygen absorption, they can be suitably used for packaging medicines and supplements.

100, 100A, 100B, 100C, 100D Drug packaging sheet 110 Moisture-proof layer 110A Auxiliary moisture-proof layer 120 First adhesive layer 130 Oxygen barrier layer 130A Auxiliary oxygen barrier layer 140 Second adhesive layer 150 Oxygen absorbing layer 160 Seal layer 170 Deodorant layer 200 Drug Package 210 Pocket 300 Blister Pack for Drug Packaging 400 Sealing Member 500 Non-contact Oxygen Meter 510 Sensor Chip for Measuring Oxygen Concentration

Claims (12)

A drug packaging sheet comprising a plurality of resin layers,
The oxygen-absorbing layer is composed of a resin composition containing a base resin, an oxygen-absorbing resin A, and a reaction accelerator. The drug packaging sheet according to claim 1, further comprising an oxygen barrier layer. The drug packaging sheet according to claim 2, wherein the drug packaging sheet has the oxygen absorbing layer, the oxygen barrier layer, and the moisture-proof layer in this order. The drug packaging sheet according to claim 2 or 3, wherein the oxygen barrier layer has an oxygen-absorbing resin B. The drug packaging sheet according to claim 1, wherein in the resin composition, the oxygen-absorbing resin A is contained in an amount of 1 wt% or more and 80 wt% or less. The drug packaging sheet according to any one of claims 1 to 5, wherein a content of the reaction accelerator in the resin composition is 100 ppm or more and 10,000 ppm or less with respect to the resin composition. The moisture-proof layer contains a thermoplastic resin, and the water vapor permeability of the thermoplastic resin is 40 ° C. and 90% RH, and the water vapor permeability at a thickness of 25 μm is 100 g / m ² · day or less. 7. The medicine packaging sheet according to any one of 6 above. The total light transmittance of the said medicine packaging sheet is 70% or more, The medicine packaging sheet in any one of Claims 1-7. A blister pack for medicine packaging obtained by molding the medicine packaging sheet according to any one of claims 1 to 8. A drug packaging body including a sealing member and a blister pack for drug packaging, wherein the blister pack for drug packaging includes the blister pack for drug packaging according to claim 9. It is a chemical | medical agent packaging body containing a sealing member and a blister pack for chemical | medical agent packaging, Comprising: The said pharmaceutical packaging body containing the sheet | seat for pharmaceutical packaging in any one of Claims 1-10. A medicine packaging body including a sealing member and a medicine packaging blister pack, wherein the sealing member includes the medicine packaging sheet according to any one of claims 1 to 8, and the medicine packaging blister pack. A drug package comprising the blister pack for drug packaging according to claim 9.